Personalis Satellite Symposium

Presenters:  
Erin N. Newburn, PhD, Director, Field Applications Scientist 
Dan Norton, MBA, Sr. Product Manager

"NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics"

NeXT Liquid Biopsy™, a first-of-its-kind, high-performance exome-wide liquid biopsy assay, is designed to complement ImmunoID NeXT™, providing a unique ability to evaluate the cancer ecosystem, and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and the blood.  

NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples. 

Any questions? Contact:

Ted van der Lende
Sr Director Strategic Business Development Europe
ted.vanderlende@personalis.com
+31627311557

Jennifer Havlek
Director, Marketing Communications
jennifer.havlek@personalis.com 
650-282-8901

Live chat

If you see a 'Let's chat' icon on the bottom right of the page, it means that a representative is online and ready to chat and answer your questions! Click on the icon to chat with them.

If you see a 'Send message' button it means nobody is online right now, but you can send an email instead.